Ibrutinib emerged as an important and effective treatment for chronic lymphocytic leukemia (CLL) by inhibiting BTK and thereby blocking the PLCγ2 signaling pathway 6. Here, PLCG2 is linked to B-cell chronic lymphocytic leukemia.